secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYCOR MEDICAL INC (VYCO)
CIK:        0001424768
Form:       8-K
Filed at:   2026-05-15T19:42:28+00:00
Accession:  0001493152-26-023666
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vycor Medical Q1 2026 revenue up 5% to $458,540; turns to operating profit of $45,808
--------------------------------------------------------------------------------

- Revenue $458,540 (+5% YoY); Vycor Medical division contributed $440,441.
- Operating profit of $45,808 vs operating loss of $(12,806) in Q1 2025.
- Non-GAAP operating profit $59,788, up from $20,388 YoY; cash expenses down to $315,365.
- Gross margin steady at 82% for Vycor Medical; two new peer-reviewed VBAS studies published.
- NovaVision revenue $18,099, still in development stage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1424768/000149315226023666/0001493152-26-023666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1424768/000149315226023666/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-023666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer